Neumora Therapeutics IncNASDAQ:NMRA
- LAST PRICE11.8100
- TODAY'S CHANGE (%)0.2000 (1.7227%)
- Bid / Lots11.8000/ 3
- Ask / Lots11.8300/ 2
- Open / Previous Close11.5000 / 11.6100
- Day Range
- 52 Week Range
- Volume355,733
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | NMRA |
|---|---|---|
| 09:32 ET | 11335 | 11.54 |
| 09:36 ET | 200 | 11.62 |
| 09:38 ET | 2015 | 11.56 |
| 09:39 ET | 900 | 11.62 |
| 09:43 ET | 1960 | 11.7 |
| 09:45 ET | 2000 | 11.63 |
| 09:48 ET | 4338 | 11.7 |
| 09:52 ET | 600 | 11.68 |
| 09:56 ET | 400 | 11.685 |
| 09:57 ET | 72522 | 11.8368 |
| 09:59 ET | 12798 | 11.78 |
| 10:01 ET | 400 | 11.785 |
| 10:03 ET | 11809 | 11.67 |
| 10:06 ET | 900 | 11.65 |
| 10:08 ET | 2612 | 11.6 |
| 10:10 ET | 1206 | 11.575 |
| 10:12 ET | 800 | 11.58 |
| 10:14 ET | 4784 | 11.52 |
| 10:15 ET | 8065 | 11.545 |
| 10:17 ET | 700 | 11.57 |
| 10:19 ET | 1300 | 11.595 |
| 10:21 ET | 30996 | 11.78 |
| 10:24 ET | 7012 | 11.72 |
| 10:26 ET | 1062 | 11.74 |
| 10:28 ET | 6125 | 11.7306 |
| 10:30 ET | 1926 | 11.69 |
| 10:32 ET | 1000 | 11.685 |
| 10:33 ET | 1700 | 11.715 |
| 10:35 ET | 7824 | 11.725 |
| 10:37 ET | 2000 | 11.81 |
| 10:39 ET | 1752 | 11.81 |
| 10:42 ET | 800 | 11.79 |
| 10:44 ET | 4124 | 11.825 |
| 10:46 ET | 700 | 11.81 |
| 10:48 ET | 1900 | 11.845 |
| 10:50 ET | 1500 | 11.83 |
| 10:51 ET | 3414 | 11.83 |
| 10:53 ET | 9860 | 11.765 |
| 10:55 ET | 2812 | 11.77 |
| 10:57 ET | 4679 | 11.825 |
| 11:00 ET | 5148 | 11.85 |
| 11:02 ET | 1311 | 11.8758 |
| 11:04 ET | 5990 | 11.91 |
| 11:06 ET | 1110 | 11.92 |
| 11:08 ET | 2080 | 11.99 |
| 11:09 ET | 2956 | 11.985 |
| 11:11 ET | 33710 | 11.92 |
| 11:13 ET | 825 | 11.93 |
| 11:15 ET | 2048 | 11.89 |
| 11:18 ET | 1150 | 11.8 |
| 11:20 ET | 527 | 11.83 |
| 11:22 ET | 1072 | 11.83 |
| 11:24 ET | 4793 | 11.8 |
| 11:26 ET | 1076 | 11.825 |
| 11:27 ET | 200 | 11.825 |
| 11:29 ET | 1500 | 11.81 |
Jul 8, 2024
DJ Neumora Therapeutics Initiated at Outperform by Mizuho, from 6:57AM ET on Monday Jul 08, 2024 by Dow Jones
6:57AM ET on Monday Jul 08, 2024 by Dow Jones
Jun 20, 2024
Neumora Therapeutics Announces Initiation of Phase 1b Study of NMRA-511 for Treatment of Alzheimer's Disease Agitation, from 7:00AM ET on Thursday Jun 20, 2024 by Dow Jones
7:00AM ET on Thursday Jun 20, 2024 by Dow Jones
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
Neumora Therapeutics Inc | 1.9B | -7.6x | --- |
Keros Therapeutics Inc | 1.8B | -10.4x | --- |
Akero Therapeutics Inc | 1.9B | -8.8x | --- |
Verona Pharma PLC | 1.7B | -26.7x | --- |
Soleno Therapeutics Inc | 1.7B | -19.2x | --- |
Kura Oncology Inc | 1.7B | -10.6x | --- |
Company Information
Neumora Therapeutics Inc. is a clinical-stage biopharmaceutical company. The Company’s therapeutic pipeline consists of seven clinical and preclinical neuroscience programs that target novel mechanisms of action for a broad range of underserved neuropsychiatric disorders and neurodegenerative diseases. Its advanced product candidate, navacaprant (NMRA-140), is a novel once-daily oral kappa opioid receptor (KOR) antagonist that is being developed for the treatment of depressive disorder (MDD). Its other candidates include NMRA-266, NMRA-511, and NMRA-NMDA. NMRA-266 is a positive allosteric modulator program of the M4 muscarinic receptor (M4R) for the treatment of schizophrenia. NMRA-266 is designed to be selective for the M4 receptor subtype of the muscarinic receptor family. NMRA-511 is an investigational antagonist of the vasopressin 1a receptor (V1aR). NMRA-NMDA is an NMDA positive allosteric modulator program that the Company is developing for the treatment of schizophrenia.
Contact Information
- Headquarters
- 490 Arsenal Way, Suite 200WATERTOWN, MA, United States 02472
- Phone
- 857-760-0900
- Fax
- 302-655-5049
Executives
- Executive Chairman of the Board, Co-Founder
- Paul Berns
- President, Chief Executive Officer, Director
- Henry Gosebruch
- Co-Founder, Chief Operating Officer
- Carol Suh
- Chief Financial Officer
- Joshua Pinto
- Chief Strategy Officer
- Daljit Aurora
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $1.9B |
|---|---|
Revenue (TTM) | $0.00 |
Shares Outstanding | 159.5M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | --- |
EPS | $-1.55 |
Book Value | $2.95 |
P/E Ratio | -7.6x |
Price/Sales (TTM) | --- |
Price/Cash Flow (TTM) | --- |
Operating Margin | --- |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
